STERIS (NYSE:STE) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

STERIS (NYSE:STE) released its quarterly earnings data on Monday. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03), FiscalAI reports. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. STERIS updated its FY 2027 guidance to 11.100-11.300 EPS.

STERIS Trading Down 2.7%

Shares of NYSE:STE traded down $5.50 during trading hours on Monday, hitting $201.95. 1,011,024 shares of the company’s stock traded hands, compared to its average volume of 773,466. The business has a fifty day moving average price of $224.30 and a 200-day moving average price of $244.27. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. STERIS has a 1 year low of $195.14 and a 1 year high of $269.44. The firm has a market capitalization of $19.81 billion, a P/E ratio of 28.17 and a beta of 0.95.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s payout ratio is 35.15%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on STE shares. Weiss Ratings cut STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, April 16th. Wall Street Zen cut STERIS from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $275.20.

Insider Buying and Selling at STERIS

In related news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the transaction, the director owned 705 shares of the company’s stock, valued at $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.07% of the company’s stock.

Institutional Investors Weigh In On STERIS

Large investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp boosted its stake in shares of STERIS by 46.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock worth $251,000 after acquiring an additional 349 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in STERIS by 32.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock valued at $55,015,000 after acquiring an additional 59,264 shares during the last quarter. Empowered Funds LLC increased its holdings in shares of STERIS by 16.1% during the 1st quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock worth $522,000 after buying an additional 319 shares during the last quarter. Woodline Partners LP increased its holdings in STERIS by 40.0% in the 1st quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after purchasing an additional 2,372 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in STERIS by 38.9% in the 1st quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after purchasing an additional 5,803 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.